AVITA Medical, Inc. (RCEL) AI Stock Analysis

AVITA Medical, Inc. operates as a regenerative tissue company with commercial operations across the United States, Australia, and the United Kingdom. It specializes in regenerative products for burn injuries, trauma injuries, chronic wounds, and dermatological conditions such as vitiligo. The company's platform uses a patient's own skin cells, anchored by its RECELL System device that enables clinicians to prepare Spray-On Skin cells for treating acute thermal burns in adult patients. Founded in 2000 and based in Valencia, California, AVITA conducts research collaborations with the University of Colorado School of Medicine and Houston Methodist Research Institute.

AVITA Medical increased annual revenue from $33.0M in FY2021 to $71.6M in FY2025, reflecting a 5-year revenue CAGR of 67.7%. Annual revenue growth was 512.0% in FY2021, 4.2% in FY2022, 45.7% in FY2023, 28.1% in FY2024, and 11.5% in FY2025. Gross margin stood at 82.1% in FY2025, compared to 85.8% in FY2024 and 81.5% in FY2021. Operating losses persisted across all years, with operating margin at -59.4% and net income at -$48.6M in FY2025, following a net loss of -$61.8M in FY2024. For the trailing twelve months ended June 30, 2026, revenue totaled $75.6M with quarterly revenue growth of 17.8% year-over-year and an operating margin of -31.6%.

As of June 30, 2026, AVITA Medical held $11.1M in cash and short-term investments against $48.5M in total debt, yielding net debt of $37.3M. The company had a current ratio of 0.41 and negative shareholders' equity of -$27.8M on total assets of $47.8M. In FY2025, operating cash flow was -$31.2M and free cash flow was -$32.9M, with capital expenditures of $1.7M. In addition, its share count expanded by 26.2% over 5 years.

At a last close of $13.04, AVITA Medical traded at a market capitalization of $403.3M and an enterprise value of $375.4M. Its forward P/E of 10.3x sits below the 17.3x median of its US-listed Healthcare peers, while its price-to-sales multiple of 5.3x is higher than the peer median of 4.1x. Over the past year, the stock returned 142.4%, outpacing the 16.8% return of the S&P 500 benchmark. However, its 5-year return of -24.9% trailed the S&P 500 return of 83.0%.

AVITA Medical holds 3 Strong Buy ratings and no Buy, Hold, Sell, or Strong Sell ratings among analysts. The mean price target is $13.41, representing 2.9% above the last close of $13.04. For the fiscal year ending December 31, 2026, analysts estimate revenue of $124.1M and EPS of $0.42. For the subsequent fiscal year, 4 analysts estimate revenue of $156.1M and EPS of -$0.60. AVITA has beaten EPS estimates in 2 of the last 4 quarters, with the next earnings date scheduled for November 5, 2026.

This page is an AI-written research summary of AVITA Medical, Inc. (RCEL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RCEL income statement, RCEL balance sheet, RCEL key metrics, RCEL analyst forecast, RCEL chart. See the RCEL stock overview for the latest quote and news.